Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Alina SoareHermina A GyörfiAlexandru Emil MateiClara DeesSimon RauberThomas WohlfahrtChih-Wei ChenIngo LudolphRaymund E HorchTobias BäuerleStephan von HörstenCarina MihaiAnastasiia KozlovaAndreas RammingLarissa Valor-MéndezJörg H W DistlerPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
DPP-4 characterizes a population of activated fibroblasts and shows that DPP-4 regulates TGFβ-induced fibroblast activation in the fibrotic skin of SSc patients. Inhibition of DPP4 exerts potent antifibrotic effects when administered in well-tolerated doses. As DPP4 inhibitors are already in clinical use for diabetes, these results may have direct translational implications for the treatment of fibrosis in patients with SSc.
Keyphrases
- systemic sclerosis
- end stage renal disease
- interstitial lung disease
- type diabetes
- cardiovascular disease
- newly diagnosed
- chronic kidney disease
- idiopathic pulmonary fibrosis
- peritoneal dialysis
- extracellular matrix
- risk assessment
- signaling pathway
- oxidative stress
- rheumatoid arthritis
- transforming growth factor
- adipose tissue
- skeletal muscle
- wound healing
- endothelial cells
- climate change
- human health